Cisplatin News and Research

RSS

Combination therapy for ovarian cancer leads to greater toxicity

Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.

12 Oct 2010

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

11 Oct 2010

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.

11 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Anticancer drug Cisplatin induces side effects

Cisplatin, an anticancer drug widely used for treating various types of tumor, can induce side effects in the short term. A team of scientists, mostly from CNRS and the Université de Nice has provided first in vitro evidence that this antitumor agent modifies the sensitivity of cellular pressure sensors. This completely novel mechanism could help to elucidate certain neurological side effects of cisplatin hitherto unexplained.

6 Oct 2010

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

4 Oct 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

DCGI approves ADXS11-001 human testing for cervix cancer

As part of approving the human testing of ADXS11-001 the lead agent for the treatment of cervix cancer of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company the Drugs Controller General of India (DCGI) required that the agent be tested to assure its safety prior to use.

23 Sep 2010

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

Platinum and light together fight cancer

Researchers continue to search for cancer treatments that effectively destroy tumor cells while protecting surrounding healthy tissue and the body. One intriguing approach involves photoactivated drugs: an inactive precursor would be administered, then the diseased tissue could be irradiated to convert the drug into its cytotoxic form locally.

14 Sep 2010

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology, analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay.

2 Sep 2010

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.

2 Sep 2010

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).

27 Aug 2010

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen today announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone.

12 Aug 2010

New insight into protein transport mechanism can improve chemotherapy treatments

A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).

10 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.

4 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Cisplatin News and Research

Combination therapy for ovarian cancer leads to greater toxicity

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Anticancer drug Cisplatin induces side effects

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

DCGI approves ADXS11-001 human testing for cervix cancer

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Platinum and light together fight cancer

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Micro-RNAs programmed cells can lead to malignant growth

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

New insight into protein transport mechanism can improve chemotherapy treatments

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News